Multiple sclerosis: What have we learned from magnetic resonance imaging studies

Archives of Internal Medicine

Volumn 158, Issue 6, 1998, Pages 565-573

  Khoury, Samia J ^a   Weiner, Howard L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CYCLOSPORIN; GADOLINIUM PENTETATE; INTERFERON BETA SERINE; PLACEBO; RECOMBINANT ALPHA INTERFERON;

CLINICAL TRIAL; COGNITION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; COGNITION; CYCLOSPORINE; GADOLINIUM DTPA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PROGNOSIS; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0032559805     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.6.565     Document Type: Review

References (97)

1. Antel JP, Arnason BGW. Demyelinating diseases. In: Wilson JD, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. 12th ed. New York, NY: McGraw-Hill Book Co; 1991:2038-2045.
2. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol. 1992;31:333-336.
3. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry. 1991;54:683-688.
4. Koopmans RA, Li DKB, Grochowski E, Cutler PJ, Paty DW. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol. 1989;25:74-81.
5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907-911.
6. Noseworthy JH. Clinical scoring methods for multiple sclerosis. Ann Neurol. 1994;36:S80-S85.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
8. Sipe JC, Knobler RL, Braheny SL, Rice GPA, Panitch HS, Oldstone MBA. A Neurologic Rating Scale (NRS) for use in multiple sclerosis. Neurology. 1984;34:1368-1372.
9. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;308: 173-180.
10. Francis DA, Bain P, Swan AV, Hughes RA. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 1991;48:299-301.
11. Bushong SC. Magnetic Resonance Imaging: Physical and Biological Principles. St Louis, Mo: Mosby-Year Book lnc; 1988.
12. Francis GS, Evans AC, Arnold DL. Neuroimaging in multiple sclerosis. Neurol Clin. 1995;13:147-171.
13. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain. 1995;118:1601-1612.
14. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988;111:927-939.
15. Gonzalez-Scarano F, Grossman RI, Galetta S, Atlas SW, Silberberg DH. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann Neurol. 1987;21: 300-306.
16. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology. 1992;42:60-63.
17. Guttmann CRG, Ahn SS, Hsu L, Kikinis R, Jolesz FA. The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroradiol. 1995;16:1481-1491.
18. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology. 1996;46:373-378.
19. Filippi M, Campi A, Martinelli V, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995; 59:540-544.
20. Filippi M, Yousry T, Campi A, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology. 1996;46:379-384.
21. Horowitz AL, Kaplan RD, Grewe G, White RT, Salberg LM. The ovoid lesion: a new MR observation in patients with multiple sclerosis. AJNR Am J Neuroradiol. 1989;10:303-305.
22. Runge VM, Price AC, Kirshner HS, Alien JH, Partain CL, James AE Jr. The evaluation of multiple sclerosis by magnetic resonance imaging. Radiographics. 1986;6:203-212.
23. Ormerod IEC, Miller DH, McDonald WI, et al. The rote of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions: a quantitative study. Brain. 1987;110:1579-1616.
24. Runge VM, Kirsch JE, Lee C, Brack MA, Garneau RA. MRI of multiple sclerosis in the brain. MRI Decisions. 1992;2-10.
25. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology. 1991;180:467-474.
26. Adams RO, Kubik CS. The morbid anatomy of demyelinative diseases. Am J Med. 1952;12:510-546.
27. Oppenheimer DR. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol. 1978;4: 151-162.
28. Tartaglino LM, Friedman DP, Flanders AE, Lublin FD, Knobler RL, Liem M. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology. 1995;195:725-732.
29. Thielen KR, Miller GM. Multiple sclerosis of the spinal cord: magnetic resonance appearance. J Comput Assist Tomogr. 1996;20:434-438.
30. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo, II: findings in multiple sclerosis. Neurology. 1993;43:2632-2637.
31. Paty DW, Oger JJF, Koopmans RA, Willoughby EW, Stewart WA, Li DKB. Magnetic resonance studies in multiple sclerosis: diagnosis, quantitation of disease burden and assessment of disease activity. In: Herndon RM, Seil FJ, eds. Multiple Sclerosis: Current Status of Research and Treatment. New York, NY: Demos Publications; 1994:131-147.
32. Willoughby EW, Grochowski E, Li DKB, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol. 1989;25:43-49.
33. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain. 1990;113:1477-1489.
34. Bastianello S, Pozzilli C, Bernardi S, et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology. 1990;40:591-595.
35. Stewart WA, Hall LD, Berry K, Paty DW. Correlation between NMR scan and brain slice data in multiple sclerosis. Lancet. 1984;2:412.
36. Stewart WA, Hall LD, Berry K, et al. Magnetic resonance imaging (MRI) in multiple sclerosis (MS): pathological correlation studies in eight cases. Neurology. 1986:36(suppl 1):320.
37. Koopmans RA, Li DKB, Oger JJF, et al. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Ann Neurol. 1989;26:248-256.
38. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol. 1991;29:548-555.
39. Frank JA, Stone LA, Smith ME, Albert PS, Maloni H, McFarland HF. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol. 1994;36: S86-S90.
40. Knoury SJ, Guttmann CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology. 1994;44:2120-2124.
41. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Heurosurg Psychiatry. 1996;60:15-19.
42. Ui M, Hodgson T, Gawne-Cain M, et al. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;60:339-341.
43. Wicks DAG, Tofts PS, Miller DH, et al. Volume measurement of multiple sclerosis lesions with magnetic resonance images: a preliminary study. Neuroradiology. 1992;34:475-479.
44. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neural. 1993;33:480-489.
45. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 1994;44:635-641.
46. Filippi M, Horsfield MA, Campi A, Mammi S, Pereira C, Comi G. Resolution-dependent estimates of lesion volumes in magnetic resonance imaging studies of the brain in multiple sclerosis. Ann Neurol. 1995;38:749-754.
47. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology. 1995;45:1808-1814.
48. Broderick JP, Narayan S, Gaskill M, Dhawan AP, Khoury J. Volumetric measurement of multifocal brain lesions: implications for treatment trials of vascular dementia and multiple sclerosis. J Neuroimag. 1996;6:36-43.
49. Isaac C, Li DKB, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology. 1988;38:1511-1515.
50. Koopmans RA, Li DKB, Oger JJF, Mayo J, Paty DW. The lesion of multiple sclerosis: imaging of acute and chronic stages. Neurology. 1989;39: 959-963.
51. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
52. Gonzalez CF, Vinitski S, Seshagiri S, Lublin FD, Knobler RL. Volumetric regional analysis of MS lesions of the brain using 3D segmentation. Neurology. 1994;44(suppl 2):A339-A340.
53. Jackson EF, Narayana PA, Wolinsky JS, Doyle TJ. Accuracy and reproducibility in volumetric analysis of multiple sclerosis lesions. J Comput Assist Tomogr. 1993;17:200-205.
54. Cline HE, Lorensen WE, Kikinis R, Jolesz F. Three-dimensional segmentation of MR images of the head using probability and connectivity. J Comput Assist Tomogr. 1990;14:1037-1045.
55. Cline HE, Lorensen WE, Souza SP, et al. 3D surface rendered MR images of the brain and its vasculature. J Comput Assist Tomogr. 1991;15:344-351.
56. Mitchell JR, Karlik SJ, Lee DH, Fenster A. Computer-assisted identification and quantification of multiple sclerosis lesions in MR imaging volumes in 0he brain. J Magn Reson Imaging. 1994; 4:197-208.
57. Paty DW, McFarlin DE, McDonald WI. Magnetic resonance imaging and laboratory aids in the diagnosis of multiple sclerosis. Ann Neurol. 1991; 29:3-5.
58. Paty DW, Oger JJF, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1988; 38:180-185.
59. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology. 1988;38:1822-1825.
60. Offenbacher H, Fazekas F, Schmidt R, et al. Assessment of MRI criteria for a diagnosis of MS. Neurology. 1993;43:905-909.
61. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med. 1993;329:1764-1769.
62. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain. 1993;116:135-146.
63. Miller DH, Cormerod IE, McDonald WI, et al. The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry. 1988;51:1569-1571.
64. Miller DH. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol. 1994; 36:S91-S94.
65. Edwards MK, Farlow MR, Stevens JC. Multiple sclerosis: MRI and clinical correlation. AJR Am J Roentgenol. 1986;147:571-574.
66. 2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 1995;45:255-260.
67. Weiner HL, Guttman CRG, Khoury SJ, et al. Correlation of magnetic resonance imaging with immune and clinical measures in 45 MS patients receiving 20-24 MRI scans each over a one year period. Presented at the 47th Annual Meeting of the American Academy of Neurology; May 10, 1995; Seattle, Wash. Abstract WIP1.
68. Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzalez-Scarano F. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology. 1988;169:117-122.
69. Huber SJ, Paulson GW, Shuttleworth EC, et al. Magnetic resonance imaging correlates of dementia in multiple sclerosis. Arch Neurol. 1987; 44:732-736.
70. Rao SM, Leo GJ, Haughton VW, St Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology. 1989;39: 161-166.
71. Franklin GM, Heaton RK, Nelson LM, Filley CM, Seibert C. Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. Neurology. 1988;38:1826-1829.
72. Parti F, Di Stefano M, De Pascalis D, et al. May there exist specific MRI findings predictive of dementia in multiple sclerosis patients? Fund Neurol 1995;10:83-90.
73. Arnett PA, Rao SM, Bernardin L, Grafman J, Yetkin FZ, Lobeck L. Relationship between frontal lobe lesions and Wisconsin Card Sorting Test performance in patients with multiple sclerosis. Neurology. 1994;44:420-425.
74. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis: US National MS Society Task Force. Ann Neurol. 1996; 39:6-16.
75. Kappos L, Städt D, Ratzka M, et al. Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis. Neuroradiology. 1988;30:299-302.
76. Koopmans RA, Li DKB, Zhao GJ, Redekop WK, Paty DW. MRI assessment of cyclosporine therapy of MS in a multi-center trial. Neurology. 1992;42 (suppl 3):210. Abstract.
77. Kastrukoff LF, Oger JJ, Hashimoto SA, et al. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis, I: clinical and MRI evaluation. Neurology. 1990;40:479-486.
78. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant Interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 1994;44:406-413.
79. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
80. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
81. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
82. Miller DH. Magnetic resonance imaging and spectroscopy in multiple sclerosis. Curr Opin Neurol. 1995;8:210-215.
83. Thomas DJ, Pennock JM, Hajnal JV, Young IR, Bydder GM, Steiner RE. Magnetic resonance imaging of spinal cord in multiple sclerosis by fluid-attenuated inversion recovery. Lancet. 1993;341: 593-594.
84. De Coene B, Hajnal JV, Pennock JM, Bydder GM. MRI of the brain stem using fluid attenuated inversion recovery pulse sequences. Neuroradiology. 1993;35:327-331.
85. Dousset V, Grossman RI, Ramer KN, et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology. 1992;182: 483-491.
86. Loevner LA, Grossman RI, Cohen JA, Lexa FJ, Kessler D, Kolson DL. Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis: assessment with magnetization-transfer measurements. Radiology. 1995;196:511-515.
87. Filippi M, Campi A, Dousset V, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology. 1995;45:478-482.
88. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hänicke W, Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med. 1989;9:79-93.
89. Arnold DL, De Stefano N, Collins DL, et al. Imaging of axonal damage in multiple sclerosis. Neurology. 1994;44(suppl 2):A340.
90. Koopmans RA, Li DKB, Zhu G, Allen PS, Penn A, Paty DW. Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products. Lancet. 1993;341:631-632.
91. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology. 1990;40:1764-1769.
92. Uhlenbrock D, Sehlen S. The value of T1-weighted images in the differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE). Neuroradiology. 1989; 31:203-212.
93. Hiehle JF Jr, Lenkinski RE, Grossman RI, et al. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn Reson Med. 1994;32: 285-293.
94. Loevner LA, Grossman RI, McGowan JC, Ramer KN, Cohen JA. Characterization of multiple sclerosis plaques with T1-weighted MR and quantitative magnetization transfer. AJNR Am J Neuroradiol. 1995;16:1473-1479.
95. Hiehle JF Jr, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spinecho images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol. 1995;16: 69-77.
96. Van Walderveen MAA, Scheltens P, Barkhof F, et al. Histopathologic correlates of hypointense lesions on T1-weighted SE MR images in multiple sclerosis. J Neurol. 1996;243(suppl 2):S18. Abstract 92.
97. 1-weighted) spin-echo images. Neurology. 1995; 45:1684-1690.